Perioperative systemic therapy versus cytoreductive surgery and HIPEC alone for resectable colorectal peritoneal metastases

Publikováno v: Annals of Surgical Oncology. 30(5):2678-2688

Background As part of a randomized phase II trial in patients with isolated resectable colorectal peritoneal metastases (CPMs), the present study compared patient-reported outcomes (PROs) of patients treated with perioperative systemic therapy versus

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=dris___00893::381aee15879aa2e3ca43b6718a3afc33
http://www.scopus.com/inward/record.url?scp=85147665951&partnerID=8YFLogxK

BAP1 Loss by Immunohistochemistry Predicts Improved Survival to First-Line Platinum and Pemetrexed Chemotherapy for Patients With Pleural Mesothelioma: A Validation Study

Autor: Amber Louw, Vasiliki Panou, Weronika Maria Szejniuk, Christos Meristoudis, Siaw Ming Chai, Chris van Vliet, Y. C. Gary Lee, Ian M. Dick, Tina Firth, Louise Andersen Lynggaard, Azadeh Birbaneh Asghari, Mogens Vyberg, Johnni Hansen, Jenette Creaney, Oluf Dimitri Røe

Publikováno v: Louw, A, Panou, V, Szejniuk, W M, Meristoudis, C, Chai, S M, van Vliet, C, Lee, Y C G, Dick, I M, Firth, T, Lynggaard, L A, Asghari, A B, Vyberg, M, Hansen, J, Creaney, J & Røe, O D 2022, ' BAP1 Loss by Immunohistochemistry Predicts Improved Survival to First-Line Platinum and Pemetrexed Chemotherapy for Patients With Pleural Mesothelioma : A validation study ', Journal of Thoracic Oncology, vol. 17, no. 7, pp. 921-930 . https://doi.org/10.1016/j.jtho.2022.04.008

INTRODUCTION: Pleural mesothelioma (PM) is an aggressive malignancy with no identified predictive biomarkers. We assessed whether tumor BAP1 status is a predictive biomarker for survival in patients receiving first-line combination platinum and pemet

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::56d4a12d531cfba9a0343a260fa2c6f6
https://doi.org/10.1016/j.jtho.2022.04.008

Determining clinical course of diffuse large B-cell lymphoma using targeted transcriptome and machine learning algorithms

Autor: Maher Albitar, Hong Zhang, Andre Goy, Zijun Y. Xu-Monette, Govind Bhagat, Carlo Visco, Alexandar Tzankov, Xiaosheng Fang, Feng Zhu, Karen Dybkaer, April Chiu, Wayne Tam, Youli Zu, Eric D. Hsi, Fredrick B. Hagemeister, Jooryung Huh, Maurilio Ponzoni, Andrés J. M. Ferreri, Michael B. Møller, Benjamin M. Parsons, J. Han van Krieken, Miguel A. Piris, Jane N. Winter, Yong Li, Bing Xu, Ken H. Young

Publikováno v: Blood Cancer Journal, Vol 12, Iss 2, Pp 1-9 (2022)
Blood Cancer Journal, 12
Blood Cancer Journal, 12, 2
Albitar, M, Zhang, H, Goy, A, Xu-Monette, Z Y, Bhagat, G, Visco, C, Tzankov, A, Fang, X, Zhu, F, Dybkaer, K, Chiu, A, Tam, W, Zu, Y, Hsi, E D, Hagemeister, F B, Huh, J, Ponzoni, M, Ferreri, A J M, Møller, M B, Parsons, B M, van Krieken, J H, Piris, M A, Winter, J N, Li, Y, Xu, B & Young, K H 2022, ' Determining clinical course of diffuse large B-cell lymphoma using targeted transcriptome and machine learning algorithms ', Blood Cancer Journal, vol. 12, no. 2, 25 . https://doi.org/10.1038/s41408-022-00617-5
Albitar, M, Zhang, H, Goy, A H, Xu-Monette, Z, Bhagat, G, Visco, C, Tzankov, A, Fang, X, Zhu, F, Dybkaer, K, Chiu, A, Tam, W, Zu, Y, Hsi, E D, Hagemeister, F B, Huh, J, Ponzoni, M, Ferreri, A J M, Moller, M, Parsons, B M, Van Krieken, J H J M, Piris, M A, Winter, J N, Li, Y, Xu, B & Young, K H 2021, ' Determining Clinical Course of Diffuse Large B-Cell Lymphoma Using Targeted Transcriptome and Machine Learning Algorithms ', Blood, vol. 138, no. Suppl. 1, 2395 . https://doi.org/10.1182/blood-2021-148841
Blood Cancer Journal

Introduction: Multiple studies have demonstrated that diffuse large B-cell lymphoma (DLBCL) can be divided into subgroups based on their biology. However, these biological subgroups overlap clinically. While R-CHOP (rituximab, cyclophosphamide, doxor

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9c9ae5e528b2a56ac4958ad97d7f7744
https://doaj.org/article/93888a803eda4609ab485bda57596d9c

Sixty-Day Mortality of Patients With Metastatic Colorectal Cancer Randomized to Systemic Treatment vs Primary Tumor Resection Followed by Systemic Treatment

Autor: van der Kruijssen, Dave E W, Elias, Sjoerd G, Vink, Geraldine R, van Rooijen, Karlijn L, 't Lam-Boer, Jorine, Mol, Linda, Punt, Cornelis J A, de Wilt, Johannes H W, Koopman, Miriam, De Hingh, Ignace

Publikováno v: JAMA Surgery, 156(12), 1093-1101. American Medical Association
JAMA Surgery, 156, 1093-1101
van der Kruijssen, D E W, Elias, S G, Vink, G R, van Rooijen, K L, 't Lam-Boer, J, Mol, L, Punt, C J A, de Wilt, J H W, Koopman, M, CAIRO4 Working Group & Liposits, G 2021, ' Sixty-Day Mortality of Patients With Metastatic Colorectal Cancer Randomized to Systemic Treatment vs Primary Tumor Resection Followed by Systemic Treatment : The CAIRO4 Phase 3 Randomized Clinical Trial ', JAMA Surgery, vol. 156, no. 12, pp. 1093-1101 . https://doi.org/10.1001/jamasurg.2021.4992
Hepatobiliary Surg Nutr
JAMA Surgery, 156, 12, pp. 1093-1101
JAMA surgery, 156(12), 1093-1101. American Medical Association

Importance: The role of primary tumor resection (PTR) in synchronous patients with metastatic colorectal cancer (mCRC) who had unresectable metastases and few or absent symptoms of their primary tumor is unclear. Studying subgroups with low postopera

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7470bc88069f37e4667edff67f2db26d
https://doi.org/10.1001/jamasurg.2021.4992

Spleen tyrosine kinase/FMS-like tyrosine kinase-3 inhibition in relapsed/refractory B-cell lymphoma, including diffuse large B-cell lymphoma : updated data with mivavotinib (TAK-659/CB-659)

Autor: Gordon, Leo I, Karmali, Reem, Kaplan, Jason B, Popat, Rakesh, Burris, Howard A, Ferrari, Silvia, Madan, Sumit, Patel, Manish R, Gritti, Giuseppe, El-Sharkawi, Dima, Chau, F Ian, Radford, John, de Oteyza, Jaime Pérez, Zinzani, Pier Luigi, Iyer, Swaminathan P, Townsend, William, Miao, Harry, Proscurshim, Igor, Wang, Shining, Katyayan, Shilpi, Yuan, Ying, Zhu, Jiaxi, Stumpo, Kate, Shou, Yaping, Carpio, Cecilia, Bosch, Francesc

Publikováno v: Gordon, L I, Karmali, R, Kaplan, J B, Popat, R, Burris, H A, Ferrari, S, Madan, S, Patel, M R, Gritti, G, El-Sharkawi, D, Chau, F I, Radford, J, de Oteyza, J P, Zinzani, P L, Iyer, S P, Townsend, W, Miao, H, Proscurshim, I, Wang, S, Katyayan, S, Yuan, Y, Zhu, J, Stumpo, K, Shou, Y, Carpio, C & Bosch, F 2023, ' Spleen tyrosine kinase/FMS-like tyrosine kinase-3 inhibition in relapsed/refractory B-cell lymphoma, including diffuse large B-cell lymphoma : updated data with mivavotinib (TAK-659/CB-659) ', Oncotarget, vol. 14, pp. 57-70 . https://doi.org/10.18632/oncotarget.28352
Scientia

Non-Hodgkin’s lymphoma; SYK inhibitor; Relapsed/refractory Linfoma no Hodgkin; Inhibidor de SYK; Recidivante/refractario Limfoma no Hodgkin; Inhibidor de SYK; Recaiguda/refractària We report an updated analysis from a phase I study of the spleen t

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::611458e735d4ba1168636765aa9dcd81
https://ddd.uab.cat/record/271599